Greater Cannabis Company (GCAN) Income towards Parent Company (2017 - 2026)
Greater Cannabis Company's (GCAN) quarterly Income towards Parent Company came in at -$33376.0 in Q1 2026, up 67.76% year-on-year from -$19895.6 in Q1 2025, and down 109.88% quarter-over-quarter from $337757.0 in Q4 2025.
Greater Cannabis Company (GCAN) Income towards Parent Company (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$33376.0 for Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 67.76% year-over-year to -$33376.0 in Q1 2026; TTM through Mar 2026 was -$122571.0, a 48.49% increase from a year earlier, with the FY2025 full-year figure at -$331612.0, down 85.22% from the prior year.
- Income towards Parent Company eased to -$33376.0 in Q1 2026 per GCAN's latest filing, from $337757.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $337757.0 in Q4 2025 and bottomed at -$390853.0 in Q2 2025.
- The 5-year median for Income towards Parent Company is -$46165.0 (2024), against an average of -$56105.5.
- Biggest YoY gain for Income towards Parent Company was 879.18% in 2025; the steepest drop was 770.17% in 2025.
- Year by year, Income towards Parent Company stood at -$47401.0 in 2022, then gained by 1.14% to -$46861.0 in 2023, then rose by 7.5% to -$43348.0 in 2024, then soared by 879.18% to $337757.0 in 2025, then tumbled by 109.88% to -$33376.0 in 2026.
- Per Business Quant, the three latest GCAN Income towards Parent Company figures stand at -$33376.0 (Q1 2026), $337757.0 (Q4 2025), and -$36099.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Greater Cannabis Company | 236,233.75 | 234,794.75 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | 337,757.00 |
| Sep 30, 2025 | -36,099.00 |
| Jun 30, 2025 | -390,853.00 |
| Mar 31, 2025 | -103,511.00 |
| Dec 31, 2024 | -43,348.00 |
| Sep 30, 2024 | -46,165.00 |
| Jun 30, 2024 | -44,917.00 |
| Mar 31, 2024 | -44,611.00 |
| Dec 31, 2023 | -46,861.00 |
| Sep 30, 2023 | -53,430.00 |
| Jun 30, 2023 | -45,043.00 |
| Mar 31, 2023 | -43,068.00 |
| Dec 31, 2022 | -47,401.00 |
| Sep 30, 2022 | -102,776.00 |
| Jun 30, 2022 | -62,405.00 |
| Mar 31, 2022 | -147,686.00 |
| Dec 31, 2021 | -196,331.00 |
| Sep 30, 2021 | -252,278.00 |
| Jun 30, 2021 | -38,964.00 |